Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 16/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588098 | 1.00 | RAF1 (0.35) | RAF1KCNH2BRAFCYP1A2TP53 | |
| SCHEMBL3597374 | 0.94 | TRPV1 (0.32) | TRPV1 | |
| SCHEMBL3597372 | 0.94 | TRPV1 (0.32) | TRPV1 | |
| SCHEMBL3597015 | 0.93 | TRPV1 (0.32) | TRPV1 | |
| SCHEMBL3597017 | 0.93 | TRPV1 (0.32) | TRPV1 | |
| SCHEMBL13545476 | 0.90 | TRPV1 (0.35) | TRPV1 | |
| SCHEMBL3600561 | 0.88 | TRPV1 (0.38) | TP53TRPV1 | |
| SCHEMBL3600565 | 0.88 | TRPV1 (0.38) | TP53TRPV1 | |
| SCHEMBL3598075 | 0.87 | RAF1 (0.39) | RAF1KCNH2BRAFCYP1A2TRPV1 | |
| SCHEMBL3600316 | 0.86 | TRPV1 (0.40) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | RAF1 1753/4885KCNH2 416/4885BRAF 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.